Company intelligence / Profile preview
YourChoice Therapeutics
San Francisco, California, United Statesyourchoicetx.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Other
01
Overview
YCT‑529, a first-in-class RAR-alpha inhibitor for male contraception, demonstrated high efficacy and full reversibility in preclinical models. The drug completed a successful Phase 1a safety study and entered a multi-center Phase 1b/2a trial to assess tolerability and impact on sperm count. It remains the only non-hormonal male birth control pill currently being tested in humans.
- Therapeutic areas
- Men's HealthWomen's Health
- Modalities
- Small molecules (non-hormonal oral contraceptives)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Male Contraceptive Initiative (MCI) – grant funding and program-related investment partner supporting preclinical and clinical development of YCT‑529Collaboration with Dr. Gunda Georg at University of Minnesota’s NIH-funded Contraceptive Center for medicinal chemistry support on YCT‑529 development
Beyond the preview
Go deeper on YourChoice Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YourChoice Therapeutics.